Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024 Continued preparations to launch LV portfolio...